Beneficial Effect of Statins in COVID-19–Related Outcomes—Brief Report: A National Population-Based Cohort Study
Although statins are widely prescribed lipid-lowering drugs, there are concerns about the safety of their use in the context of coronavirus disease 2019 (COVID-19), since statins increase the expression of ACE2 (angiotensin-converting enzyme 2). This study aimed to disclose the association between s...
Gespeichert in:
| Veröffentlicht in: | Arteriosclerosis, thrombosis, and vascular biology thrombosis, and vascular biology, 2021-03, Vol.41 (3), p.e175-e182 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e182 |
|---|---|
| container_issue | 3 |
| container_start_page | e175 |
| container_title | Arteriosclerosis, thrombosis, and vascular biology |
| container_volume | 41 |
| creator | Lee, Hae-Young Ahn, Juhee Park, Juhong Kyung Kang, Chang Won, Sung-Ho Wook Kim, Dong Park, Jong-Heon Chung, Ki-Hyun Joh, Joon-Sung Bang, Ji Hwan Hee Kang, Cheong Bum Pyun, Wook Oh, Myoung-don |
| description | Although statins are widely prescribed lipid-lowering drugs, there are concerns about the safety of their use in the context of coronavirus disease 2019 (COVID-19), since statins increase the expression of ACE2 (angiotensin-converting enzyme 2). This study aimed to disclose the association between statins and 60-day COVID-19 mortality. Approach and Results: All patients hospitalized with laboratory-confirmed COVID-19 were enrolled in this study from January 19 to April 16, 2020, in Korea. We evaluated the association between the use of statins and COVID-19-related mortality in the overall and the nested 1:2 propensity score-matched study. Furthermore, a comparison of the hazard ratio for death was performed between COVID-19 patients and a retrospective cohort of patients hospitalized with pneumonia between January and June 2019 in Korea. The median age of the 10 448 COVID-19 patients was 45 years. Statins were prescribed in 533 (5.1%) patients. After adjusting for age, sex, and comorbidities, Cox regression showed a significant decrease in hazard ratio associated with the use of statins (hazard ratio, 0.637 [95% CI, 0.425-0.953];
=0.0283). Moreover, on comparing the hazard ratio between COVID-19 patients and the retrospective cohort of hospitalized pneumonia patients, the use of statins showed similar benefits.
The use of statins correlates significantly with lower mortality in patients with COVID-19, consistent with the findings in patients with pneumonia. Graphic Abstract: A graphic abstract is available for this article. |
| doi_str_mv | 10.1161/ATVBAHA.120.315551 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7901529</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2486462902</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3544-2cdafeed138e5606b4220beed2a0298e6d50e8115fdec397ca575e84d3d4be913</originalsourceid><addsrcrecordid>eNpVkc1uEzEUhUcIREvhBVggL9lM8H9mWCBNQksrVQSV0q3leK6JwRkH20PVXd-hPGGfBIeEChaWfe1zjq_uV1UvCZ4QIsmb7vJq1p12E0LxhBEhBHlUHRJBec0lk4_LGU_bWkhOD6pnKX3DGHNK8dPqgDHBxLTFh1WewQDWGac9OrYWTEbBos9ZZzck5AY0X1ydva9Je397dwFeZ-jRYswmrCHd3_6aRQcWXcAmxPwWdehj8YWhZH0Km9H_KeqZTsU0D6uiKcljf_O8emK1T_Bivx9VX06OL-en9fniw9m8O68NE5zX1PTaAvSENSAklstt98tyQTWmbQOyFxgaQoTtwbB2arSYCmh4z3q-hJawo-rdLnczLtfQGxhy1F5tolvreKOCdur_l8Gt1NfwU5XRlDm2JeD1PiCGHyOkrNYuGfBeDxDGpChvJJe0xbRI6U5qYkgpgn34hmC1xaX2uFTBpXa4iunVvw0-WP7yKQK-E1wHnyGm7368hqhWoH1eqS1QJrGoKaYEs1LWZVHOfgMPbKOb</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2486462902</pqid></control><display><type>article</type><title>Beneficial Effect of Statins in COVID-19–Related Outcomes—Brief Report: A National Population-Based Cohort Study</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Lee, Hae-Young ; Ahn, Juhee ; Park, Juhong ; Kyung Kang, Chang ; Won, Sung-Ho ; Wook Kim, Dong ; Park, Jong-Heon ; Chung, Ki-Hyun ; Joh, Joon-Sung ; Bang, Ji Hwan ; Hee Kang, Cheong ; Bum Pyun, Wook ; Oh, Myoung-don</creator><creatorcontrib>Lee, Hae-Young ; Ahn, Juhee ; Park, Juhong ; Kyung Kang, Chang ; Won, Sung-Ho ; Wook Kim, Dong ; Park, Jong-Heon ; Chung, Ki-Hyun ; Joh, Joon-Sung ; Bang, Ji Hwan ; Hee Kang, Cheong ; Bum Pyun, Wook ; Oh, Myoung-don ; Korean Society of Hypertension, National Committee for Clinical Management of Emerging Infectious Diseases ; the Korean Society of Hypertension, National Committee for Clinical Management of Emerging Infectious Diseases</creatorcontrib><description>Although statins are widely prescribed lipid-lowering drugs, there are concerns about the safety of their use in the context of coronavirus disease 2019 (COVID-19), since statins increase the expression of ACE2 (angiotensin-converting enzyme 2). This study aimed to disclose the association between statins and 60-day COVID-19 mortality. Approach and Results: All patients hospitalized with laboratory-confirmed COVID-19 were enrolled in this study from January 19 to April 16, 2020, in Korea. We evaluated the association between the use of statins and COVID-19-related mortality in the overall and the nested 1:2 propensity score-matched study. Furthermore, a comparison of the hazard ratio for death was performed between COVID-19 patients and a retrospective cohort of patients hospitalized with pneumonia between January and June 2019 in Korea. The median age of the 10 448 COVID-19 patients was 45 years. Statins were prescribed in 533 (5.1%) patients. After adjusting for age, sex, and comorbidities, Cox regression showed a significant decrease in hazard ratio associated with the use of statins (hazard ratio, 0.637 [95% CI, 0.425-0.953];
=0.0283). Moreover, on comparing the hazard ratio between COVID-19 patients and the retrospective cohort of hospitalized pneumonia patients, the use of statins showed similar benefits.
The use of statins correlates significantly with lower mortality in patients with COVID-19, consistent with the findings in patients with pneumonia. Graphic Abstract: A graphic abstract is available for this article.</description><identifier>ISSN: 1079-5642</identifier><identifier>ISSN: 1524-4636</identifier><identifier>EISSN: 1524-4636</identifier><identifier>DOI: 10.1161/ATVBAHA.120.315551</identifier><identifier>PMID: 33535790</identifier><language>eng</language><publisher>United States: Lippincott Williams & Wilkins</publisher><subject>Adolescent ; Adult ; Aged ; Aged, 80 and over ; Child ; Child, Preschool ; Clinical and Population Studies ; Cohort Studies ; COVID-19 - complications ; COVID-19 - mortality ; COVID-19 Drug Treatment ; Diabetes Complications - drug therapy ; Diabetes Complications - mortality ; Female ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects ; Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use ; Hypertension - complications ; Hypertension - drug therapy ; Hypertension - mortality ; Infant ; Infant, Newborn ; Male ; Middle Aged ; Pandemics ; Pneumonia - drug therapy ; Pneumonia - mortality ; Propensity Score ; Proportional Hazards Models ; Pulmonary Disease, Chronic Obstructive - complications ; Pulmonary Disease, Chronic Obstructive - drug therapy ; Pulmonary Disease, Chronic Obstructive - mortality ; Republic of Korea - epidemiology ; Retrospective Studies ; SARS-CoV-2 ; Young Adult</subject><ispartof>Arteriosclerosis, thrombosis, and vascular biology, 2021-03, Vol.41 (3), p.e175-e182</ispartof><rights>Lippincott Williams & Wilkins</rights><rights>2021 American Heart Association, Inc. 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c3544-2cdafeed138e5606b4220beed2a0298e6d50e8115fdec397ca575e84d3d4be913</cites><orcidid>0000-0002-7628-1182 ; 0000-0002-5044-2742 ; 0000-0002-2344-7695 ; 0000-0001-5751-5089</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,315,781,785,886,27926,27927</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33535790$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lee, Hae-Young</creatorcontrib><creatorcontrib>Ahn, Juhee</creatorcontrib><creatorcontrib>Park, Juhong</creatorcontrib><creatorcontrib>Kyung Kang, Chang</creatorcontrib><creatorcontrib>Won, Sung-Ho</creatorcontrib><creatorcontrib>Wook Kim, Dong</creatorcontrib><creatorcontrib>Park, Jong-Heon</creatorcontrib><creatorcontrib>Chung, Ki-Hyun</creatorcontrib><creatorcontrib>Joh, Joon-Sung</creatorcontrib><creatorcontrib>Bang, Ji Hwan</creatorcontrib><creatorcontrib>Hee Kang, Cheong</creatorcontrib><creatorcontrib>Bum Pyun, Wook</creatorcontrib><creatorcontrib>Oh, Myoung-don</creatorcontrib><creatorcontrib>Korean Society of Hypertension, National Committee for Clinical Management of Emerging Infectious Diseases</creatorcontrib><creatorcontrib>the Korean Society of Hypertension, National Committee for Clinical Management of Emerging Infectious Diseases</creatorcontrib><title>Beneficial Effect of Statins in COVID-19–Related Outcomes—Brief Report: A National Population-Based Cohort Study</title><title>Arteriosclerosis, thrombosis, and vascular biology</title><addtitle>Arterioscler Thromb Vasc Biol</addtitle><description>Although statins are widely prescribed lipid-lowering drugs, there are concerns about the safety of their use in the context of coronavirus disease 2019 (COVID-19), since statins increase the expression of ACE2 (angiotensin-converting enzyme 2). This study aimed to disclose the association between statins and 60-day COVID-19 mortality. Approach and Results: All patients hospitalized with laboratory-confirmed COVID-19 were enrolled in this study from January 19 to April 16, 2020, in Korea. We evaluated the association between the use of statins and COVID-19-related mortality in the overall and the nested 1:2 propensity score-matched study. Furthermore, a comparison of the hazard ratio for death was performed between COVID-19 patients and a retrospective cohort of patients hospitalized with pneumonia between January and June 2019 in Korea. The median age of the 10 448 COVID-19 patients was 45 years. Statins were prescribed in 533 (5.1%) patients. After adjusting for age, sex, and comorbidities, Cox regression showed a significant decrease in hazard ratio associated with the use of statins (hazard ratio, 0.637 [95% CI, 0.425-0.953];
=0.0283). Moreover, on comparing the hazard ratio between COVID-19 patients and the retrospective cohort of hospitalized pneumonia patients, the use of statins showed similar benefits.
The use of statins correlates significantly with lower mortality in patients with COVID-19, consistent with the findings in patients with pneumonia. Graphic Abstract: A graphic abstract is available for this article.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Clinical and Population Studies</subject><subject>Cohort Studies</subject><subject>COVID-19 - complications</subject><subject>COVID-19 - mortality</subject><subject>COVID-19 Drug Treatment</subject><subject>Diabetes Complications - drug therapy</subject><subject>Diabetes Complications - mortality</subject><subject>Female</subject><subject>Humans</subject><subject>Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects</subject><subject>Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use</subject><subject>Hypertension - complications</subject><subject>Hypertension - drug therapy</subject><subject>Hypertension - mortality</subject><subject>Infant</subject><subject>Infant, Newborn</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Pandemics</subject><subject>Pneumonia - drug therapy</subject><subject>Pneumonia - mortality</subject><subject>Propensity Score</subject><subject>Proportional Hazards Models</subject><subject>Pulmonary Disease, Chronic Obstructive - complications</subject><subject>Pulmonary Disease, Chronic Obstructive - drug therapy</subject><subject>Pulmonary Disease, Chronic Obstructive - mortality</subject><subject>Republic of Korea - epidemiology</subject><subject>Retrospective Studies</subject><subject>SARS-CoV-2</subject><subject>Young Adult</subject><issn>1079-5642</issn><issn>1524-4636</issn><issn>1524-4636</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVkc1uEzEUhUcIREvhBVggL9lM8H9mWCBNQksrVQSV0q3leK6JwRkH20PVXd-hPGGfBIeEChaWfe1zjq_uV1UvCZ4QIsmb7vJq1p12E0LxhBEhBHlUHRJBec0lk4_LGU_bWkhOD6pnKX3DGHNK8dPqgDHBxLTFh1WewQDWGac9OrYWTEbBos9ZZzck5AY0X1ydva9Je397dwFeZ-jRYswmrCHd3_6aRQcWXcAmxPwWdehj8YWhZH0Km9H_KeqZTsU0D6uiKcljf_O8emK1T_Bivx9VX06OL-en9fniw9m8O68NE5zX1PTaAvSENSAklstt98tyQTWmbQOyFxgaQoTtwbB2arSYCmh4z3q-hJawo-rdLnczLtfQGxhy1F5tolvreKOCdur_l8Gt1NfwU5XRlDm2JeD1PiCGHyOkrNYuGfBeDxDGpChvJJe0xbRI6U5qYkgpgn34hmC1xaX2uFTBpXa4iunVvw0-WP7yKQK-E1wHnyGm7368hqhWoH1eqS1QJrGoKaYEs1LWZVHOfgMPbKOb</recordid><startdate>20210301</startdate><enddate>20210301</enddate><creator>Lee, Hae-Young</creator><creator>Ahn, Juhee</creator><creator>Park, Juhong</creator><creator>Kyung Kang, Chang</creator><creator>Won, Sung-Ho</creator><creator>Wook Kim, Dong</creator><creator>Park, Jong-Heon</creator><creator>Chung, Ki-Hyun</creator><creator>Joh, Joon-Sung</creator><creator>Bang, Ji Hwan</creator><creator>Hee Kang, Cheong</creator><creator>Bum Pyun, Wook</creator><creator>Oh, Myoung-don</creator><general>Lippincott Williams & Wilkins</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-7628-1182</orcidid><orcidid>https://orcid.org/0000-0002-5044-2742</orcidid><orcidid>https://orcid.org/0000-0002-2344-7695</orcidid><orcidid>https://orcid.org/0000-0001-5751-5089</orcidid></search><sort><creationdate>20210301</creationdate><title>Beneficial Effect of Statins in COVID-19–Related Outcomes—Brief Report: A National Population-Based Cohort Study</title><author>Lee, Hae-Young ; Ahn, Juhee ; Park, Juhong ; Kyung Kang, Chang ; Won, Sung-Ho ; Wook Kim, Dong ; Park, Jong-Heon ; Chung, Ki-Hyun ; Joh, Joon-Sung ; Bang, Ji Hwan ; Hee Kang, Cheong ; Bum Pyun, Wook ; Oh, Myoung-don</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3544-2cdafeed138e5606b4220beed2a0298e6d50e8115fdec397ca575e84d3d4be913</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Clinical and Population Studies</topic><topic>Cohort Studies</topic><topic>COVID-19 - complications</topic><topic>COVID-19 - mortality</topic><topic>COVID-19 Drug Treatment</topic><topic>Diabetes Complications - drug therapy</topic><topic>Diabetes Complications - mortality</topic><topic>Female</topic><topic>Humans</topic><topic>Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects</topic><topic>Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use</topic><topic>Hypertension - complications</topic><topic>Hypertension - drug therapy</topic><topic>Hypertension - mortality</topic><topic>Infant</topic><topic>Infant, Newborn</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Pandemics</topic><topic>Pneumonia - drug therapy</topic><topic>Pneumonia - mortality</topic><topic>Propensity Score</topic><topic>Proportional Hazards Models</topic><topic>Pulmonary Disease, Chronic Obstructive - complications</topic><topic>Pulmonary Disease, Chronic Obstructive - drug therapy</topic><topic>Pulmonary Disease, Chronic Obstructive - mortality</topic><topic>Republic of Korea - epidemiology</topic><topic>Retrospective Studies</topic><topic>SARS-CoV-2</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lee, Hae-Young</creatorcontrib><creatorcontrib>Ahn, Juhee</creatorcontrib><creatorcontrib>Park, Juhong</creatorcontrib><creatorcontrib>Kyung Kang, Chang</creatorcontrib><creatorcontrib>Won, Sung-Ho</creatorcontrib><creatorcontrib>Wook Kim, Dong</creatorcontrib><creatorcontrib>Park, Jong-Heon</creatorcontrib><creatorcontrib>Chung, Ki-Hyun</creatorcontrib><creatorcontrib>Joh, Joon-Sung</creatorcontrib><creatorcontrib>Bang, Ji Hwan</creatorcontrib><creatorcontrib>Hee Kang, Cheong</creatorcontrib><creatorcontrib>Bum Pyun, Wook</creatorcontrib><creatorcontrib>Oh, Myoung-don</creatorcontrib><creatorcontrib>Korean Society of Hypertension, National Committee for Clinical Management of Emerging Infectious Diseases</creatorcontrib><creatorcontrib>the Korean Society of Hypertension, National Committee for Clinical Management of Emerging Infectious Diseases</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Arteriosclerosis, thrombosis, and vascular biology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lee, Hae-Young</au><au>Ahn, Juhee</au><au>Park, Juhong</au><au>Kyung Kang, Chang</au><au>Won, Sung-Ho</au><au>Wook Kim, Dong</au><au>Park, Jong-Heon</au><au>Chung, Ki-Hyun</au><au>Joh, Joon-Sung</au><au>Bang, Ji Hwan</au><au>Hee Kang, Cheong</au><au>Bum Pyun, Wook</au><au>Oh, Myoung-don</au><aucorp>Korean Society of Hypertension, National Committee for Clinical Management of Emerging Infectious Diseases</aucorp><aucorp>the Korean Society of Hypertension, National Committee for Clinical Management of Emerging Infectious Diseases</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Beneficial Effect of Statins in COVID-19–Related Outcomes—Brief Report: A National Population-Based Cohort Study</atitle><jtitle>Arteriosclerosis, thrombosis, and vascular biology</jtitle><addtitle>Arterioscler Thromb Vasc Biol</addtitle><date>2021-03-01</date><risdate>2021</risdate><volume>41</volume><issue>3</issue><spage>e175</spage><epage>e182</epage><pages>e175-e182</pages><issn>1079-5642</issn><issn>1524-4636</issn><eissn>1524-4636</eissn><abstract>Although statins are widely prescribed lipid-lowering drugs, there are concerns about the safety of their use in the context of coronavirus disease 2019 (COVID-19), since statins increase the expression of ACE2 (angiotensin-converting enzyme 2). This study aimed to disclose the association between statins and 60-day COVID-19 mortality. Approach and Results: All patients hospitalized with laboratory-confirmed COVID-19 were enrolled in this study from January 19 to April 16, 2020, in Korea. We evaluated the association between the use of statins and COVID-19-related mortality in the overall and the nested 1:2 propensity score-matched study. Furthermore, a comparison of the hazard ratio for death was performed between COVID-19 patients and a retrospective cohort of patients hospitalized with pneumonia between January and June 2019 in Korea. The median age of the 10 448 COVID-19 patients was 45 years. Statins were prescribed in 533 (5.1%) patients. After adjusting for age, sex, and comorbidities, Cox regression showed a significant decrease in hazard ratio associated with the use of statins (hazard ratio, 0.637 [95% CI, 0.425-0.953];
=0.0283). Moreover, on comparing the hazard ratio between COVID-19 patients and the retrospective cohort of hospitalized pneumonia patients, the use of statins showed similar benefits.
The use of statins correlates significantly with lower mortality in patients with COVID-19, consistent with the findings in patients with pneumonia. Graphic Abstract: A graphic abstract is available for this article.</abstract><cop>United States</cop><pub>Lippincott Williams & Wilkins</pub><pmid>33535790</pmid><doi>10.1161/ATVBAHA.120.315551</doi><orcidid>https://orcid.org/0000-0002-7628-1182</orcidid><orcidid>https://orcid.org/0000-0002-5044-2742</orcidid><orcidid>https://orcid.org/0000-0002-2344-7695</orcidid><orcidid>https://orcid.org/0000-0001-5751-5089</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1079-5642 |
| ispartof | Arteriosclerosis, thrombosis, and vascular biology, 2021-03, Vol.41 (3), p.e175-e182 |
| issn | 1079-5642 1524-4636 1524-4636 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7901529 |
| source | MEDLINE; Alma/SFX Local Collection |
| subjects | Adolescent Adult Aged Aged, 80 and over Child Child, Preschool Clinical and Population Studies Cohort Studies COVID-19 - complications COVID-19 - mortality COVID-19 Drug Treatment Diabetes Complications - drug therapy Diabetes Complications - mortality Female Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use Hypertension - complications Hypertension - drug therapy Hypertension - mortality Infant Infant, Newborn Male Middle Aged Pandemics Pneumonia - drug therapy Pneumonia - mortality Propensity Score Proportional Hazards Models Pulmonary Disease, Chronic Obstructive - complications Pulmonary Disease, Chronic Obstructive - drug therapy Pulmonary Disease, Chronic Obstructive - mortality Republic of Korea - epidemiology Retrospective Studies SARS-CoV-2 Young Adult |
| title | Beneficial Effect of Statins in COVID-19–Related Outcomes—Brief Report: A National Population-Based Cohort Study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-18T03%3A46%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Beneficial%20Effect%20of%20Statins%20in%20COVID-19%E2%80%93Related%20Outcomes%E2%80%94Brief%20Report:%20A%20National%20Population-Based%20Cohort%20Study&rft.jtitle=Arteriosclerosis,%20thrombosis,%20and%20vascular%20biology&rft.au=Lee,%20Hae-Young&rft.aucorp=Korean%20Society%20of%20Hypertension,%20National%20Committee%20for%20Clinical%20Management%20of%20Emerging%20Infectious%20Diseases&rft.date=2021-03-01&rft.volume=41&rft.issue=3&rft.spage=e175&rft.epage=e182&rft.pages=e175-e182&rft.issn=1079-5642&rft.eissn=1524-4636&rft_id=info:doi/10.1161/ATVBAHA.120.315551&rft_dat=%3Cproquest_pubme%3E2486462902%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2486462902&rft_id=info:pmid/33535790&rfr_iscdi=true |